Many older people develop chronic kidney disease and are also likely to be on cholesterol-lowering drugs known as statins.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of ...

Statins, which are prescription drugs that can reduce cholesterol levels and lower the risk for heart disease, don’t affect kidney function, new research shows.

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired ...

Opens in a new tab or window The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening ... decline in estimated glomerular filtration rate (eGFR) of ≥50%, sustained ...

Annual health checkups regularly include urine tests that serve several purposes, including checking for symptoms of kidney ...

The Creve Coeur-based company is developing the use of proprietary fluorescent tracer agents as a noninvasive way to test ...

INNOVATE Corp. announced the FDA approval of the MediBeacon® Transdermal GFR System (TGFR), a groundbreaking ... individuals affected by Chronic Kidney Disease (CKD), the approval is seen as ...

Children with AAV and kidney disease face increased risks for long-term renal damage at 1 year, despite the majority achieving inactive renal disease by this time.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...